Latest news with #NeulandLaboratories
Business Standard
a day ago
- Business
- Business Standard
Neuland Laboratories consolidated net profit declines 85.80% in the June 2025 quarter
Sales decline 33.41% to Rs 292.75 crore Net profit of Neuland Laboratories declined 85.80% to Rs 13.90 crore in the quarter ended June 2025 as against Rs 97.87 crore during the previous quarter ended June 2024. Sales declined 33.41% to Rs 292.75 crore in the quarter ended June 2025 as against Rs 439.60 crore during the previous quarter ended June 2024. Particulars Quarter Ended Jun. 2025 Jun. 2024 % Var. Sales 292.75439.60 -33 OPM % 11.7828.06 - PBDT 37.76125.49 -70 PBT 17.57109.21 -84 NP 13.9097.87 -86
Time of India
15-07-2025
- Business
- Time of India
Dolly Khanna, Mukul Agrawal raise stakes in multibagger small-cap stock in June quarter
Ace investors Dolly Khanna and Mukul Mahavir Agrawal have increased their stakes in small-cap multibagger Prakash Industries during the June 2025 quarter, according to the latest shareholding data. Dolly Khanna raised her stake by 0.2%, now holding 2.27% or 40,56,674 shares in the company. Mukul Agrawal also increased his stake by 0.3%, taking his total holding to 1.72% or 30,27,554 shares. Agrawal, known for identifying multibaggers, publicly holds 62 stocks with a combined net worth of over Rs 6,896 crore as of the June quarter. His top holdings include Neuland Laboratories , BSE, Radico Khaitan , Nuvama Wealth, Deepak Fertilisers , Intellect Design , and PTC Industries . In the June quarter, Agrawal also added SME stock Monolithisch India to his portfolio, purchasing 5 lakh shares or a 2.30% stake. Additionally, he acquired a 1.27% stake in Jammu & Kashmir Bank. Meanwhile, Dolly Khanna publicly holds 16 stocks with a total net worth of over Rs 458.6 crore. Her top holdings include Som Distilleries , Mangalore Chemicals , GHCL , Polyplex Corporation , Prakash Pipes , and Stove Kraft . In Tuesday's trade, shares of Prakash Industries closed 2.6% higher at Rs 163 on the BSE. The stock has delivered multibagger returns—rising 106% in the last two years and 222% over three years. However, it is down 16% in the past one year. Prakash Industries Q4 Results While Prakash Industries reported a 5.14% year-on-year (YoY) decline in net sales to Rs 844.64 crore, net profit rose 2.32% to Rs 90.83 crore from Rs 88.77 crore in the same quarter last year. EBITDA for the quarter stood at Rs 138.43 crore, up 3.33% from Rs 133.97 crore in the March 2024 quarter. Earnings per share (EPS) also improved to Rs 5.07 from Rs 4.96 a year ago.
Economic Times
14-07-2025
- Business
- Economic Times
Neuland Laboratories shares jump 12% ahead of final dividend
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Shares of Neuland Laboratories are trading sharply higher on Monday, up 12% at Rs 13,750 amid strong buying interest. Investors holding the stock as of the record date, July 18, 2025, will be eligible to receive a final dividend of Rs 12 per dividend payout amounts to 120% of the stock's face value of Rs 10 for the financial year ending March 31, 2025, offering shareholders a healthy the past 52 weeks, Neuland Laboratories has recorded a high of Rs 18,089.55 and a low of Rs 7,900. While the stock is currently down around 23% from its 52-week high, it continues to trade significantly above its 52-week low, reflecting underlying strength and resilience in its price stock's current 14-day Relative Strength Index (RSI) stands at 54.2. The RSI is a commonly used technical indicator that measures the strength and momentum of a stock's price below 30 generally suggest the stock may be oversold (potentially undervalued), while values above 70 indicate it may be overbought (potentially overvalued). With an RSI near the middle range, the stock is currently neither oversold or a technical standpoint, Neuland Laboratories is demonstrating a strong bullish trend. The stock is trading above all eight Simple Moving Averages (SMAs) analyzed, covering periods from short-term (5-day) to long-term (200-day). This broad-based support from multiple moving averages suggests positive momentum and a generally favorable outlook among traders.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Time of India
14-07-2025
- Business
- Time of India
Neuland Laboratories shares jump 12% ahead of final dividend
Shares of Neuland Laboratories are trading sharply higher on Monday, up 12% at Rs 13,750 amid strong buying interest. Investors holding the stock as of the record date, July 18, 2025, will be eligible to receive a final dividend of Rs 12 per share. This dividend payout amounts to 120% of the stock's face value of Rs 10 for the financial year ending March 31, 2025, offering shareholders a healthy return. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Villas For Sale in Dubai Might Surprise You Dubai villas | search ads Get Deals Undo Over the past 52 weeks, Neuland Laboratories has recorded a high of Rs 18,089.55 and a low of Rs 7,900. While the stock is currently down around 23% from its 52-week high, it continues to trade significantly above its 52-week low, reflecting underlying strength and resilience in its price action. The stock's current 14-day Relative Strength Index (RSI) stands at 54.2. The RSI is a commonly used technical indicator that measures the strength and momentum of a stock's price movements. Values below 30 generally suggest the stock may be oversold (potentially undervalued), while values above 70 indicate it may be overbought (potentially overvalued). With an RSI near the middle range, the stock is currently neither oversold or overbought. Live Events From a technical standpoint, Neuland Laboratories is demonstrating a strong bullish trend. The stock is trading above all eight Simple Moving Averages (SMAs) analyzed, covering periods from short-term (5-day) to long-term (200-day). This broad-based support from multiple moving averages suggests positive momentum and a generally favorable outlook among traders. ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
&w=3840&q=100)
Business Standard
14-07-2025
- Business
- Business Standard
Mukul Agrawal portfolio pharmaceutical stock surges 10% in weak market
Neuland Laboratories share price Shares of Neuland Laboratories rallied 10 per cent to ₹13,500 on the BSE in Monday's intra-day trade in an otherwise subdued market. In the past two trading days, the stock price of the pharmaceutical company has surged 13 per cent. In comparison, the BSE Sensex was down 0.25 per cent at 82,291 at 10:31 AM. However, thus far in the calendar year 2025, Neuland has underperformed the market by falling 6 per cent, as against 4.8 per cent rise in the benchmark index. The stock had hit a record high of ₹18,089.55 on December 4, 2024. Mukul Mahavir Agrawal holds 3.12 per cent stake in Neuland Investor Mukul Mahavir Agrawal held 400,000 equity shares or 3.12 per cent stake in Neuland at the end of March 2025 quarter, the shareholding pattern data shows. Crisil Ratings reaffirms credit rating assigned to Neuland On June 20, 2025, Crisil Ratings reaffirmed its 'Crisil A+/Stable/Crisil A1' ratings on the bank loan facilities of Neuland Laboratories. The rating agency in its rationale said that the ratings continue to reflect the established market position of Neuland in the active pharmaceutical ingredient (API) segment, its established clientele, healthy business performance, product and geographical diversification, and comfortable financial risk profile. These strengths are partially offset by susceptibility to fluctuations in raw material prices, intense competition and regulatory risks, moderate working capital requirement and vulnerability of operating margin to fluctuations in foreign exchange rates, Crisil Ratings said. The custom manufacturing services (CMS) segment is set to recover in fiscal 2026 with one molecule already commercialised and one more expected to be commercialised during the fiscal. The segmental revenue will improve with more projects expected under development. With the incremental contribution from the CMS segment and healthy continuing demand from the API segment, the operating margin is expected to recover over the medium term, Crisil Ratings said. Neuland Labs - Outlook According to the management, the revenue contribution from the CMS segment will be 55 per cent - 60 per cent over the next three-to-four years. The management highlighted that since FY25 is a year of consolidation, the company's performance moderated while maintaining flattish revenue growth on a year-on-year basis. However, management is confident upon the revenue growth trajectory in FY26 on account of the completion of additional manufacturing facilities, coupled with the scaling up of commercial molecules in the CMS segment. 'We entered FY 2025-26 with renewed momentum, underscored by the completion of additional manufacturing facilities, the anticipated commercial launch of new CMS molecules, and increasing customer interest across both generic drug substances (GDS) and CMS portfolios. These developments, along with our continued focus on operational excellence and long-term capability building, strengthen our confidence in delivering sustainable growth,' Neuland said in its FY25 annual report. The diversification away from China by Western pharmaceutical companies as they look to rebalance their supply chains is also creating fresh opportunities. Neuland said, the company is well positioned to benefit from this trend, supported by a strong reputation, high-quality infrastructure, and regulatory credibility. While tariff related developments are being closely monitored, the management does not foresee a material impact, as the company's primary competitors are based outside the US, and its position as a preferred supplier to many customers helps mitigate potential disruptions. About Neuland Laboratories Neuland is a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services to customers located in around 80 countries. Regulated markets contributed more than 90 per cent to the group's revenue in fiscal 2025, while semi-regulated markets accounted for the rest. Geography-wise, Europe is the largest contributor (45 per cent of sales in fiscal 2025), followed by the US (41 per cent).
